Trial Protocol: Using genotype to tailor prescribing of nicotine replacement therapy: A randomised controlled trial assessing impact of communication upon adherence

BMC Public Health

Volumn 10, Issue , 2010, Pages

  Marteau, Theresa M ^a   Munaf, Marcus R ^b   Aveyard, Paul ^c   Hill, Chloe ^a   Whitwell, Sophia ^a   Willis, Thomas A ^a   Crockett, Rachel A ^a   Hollands, Gareth J ^a   Johnstone, Elaine C ^d   Wright, Alison J ^a   Prevost, A Toby ^a   Armstrong, David ^a   Sutton, Stephen ^e   Kinmonth, Ann Louise ^e  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GANGLION STIMULATING AGENT; MU OPIATE RECEPTOR; NICOTINE; OPRM1 PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENETICS; GENOTYPE; HUMAN; INTERPERSONAL COMMUNICATION; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NATIONAL HEALTH SERVICE; PATIENT COMPLIANCE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SMOKING CESSATION; UNITED KINGDOM;

ADULT; COMMUNICATION; ENGLAND; GANGLIONIC STIMULANTS; GENOTYPE; HUMANS; MOLECULAR TARGETED THERAPY; NICOTINE; PATIENT COMPLIANCE; QUESTIONNAIRES; RECEPTORS, OPIOID, MU; RESEARCH DESIGN; SMOKING; SMOKING CESSATION; STATE MEDICINE;

EID: 78649932960     PISSN: None     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-10-680     Document Type: Article

References (41)

1. Attitudes and knowledge about nicotine and nicotine replacement therapy. ME Mooney AM Leventhal DK Hatsukami, Nicotine & Tobacco Research 2006 8 435 446
2. Educating smokers about their cigarettes and nicotine medications. M Bansal-Travers KM Cummings A Hyland A Brown P Celestino, Health Education Research 2010 25 678 686 10.1093/her/cyp069 20064838
3. Has the revolution arrived? F Collins, Nature 2010 464 674 5 10.1038/464674a 20360716
4. A vision for the future of genomics research: A blueprint for the genomic era. FS Collins ED Green AE Guttmacher MS Guyer, Nature 2003 422 6934 835 847 10.1038/nature01626 12695777
5. Predictive genetics in primary care: expectations for the motivational impact of genetic testing affects the importance family physicians place on screening for familial cancer risk. R Gramling J Nash K Siren L Culpepper, Genetics in Medicine 2003 5 172 175 10.1097/01.GIM.0000068986.03217.BB 12792425
6. The heuristic-systematic model in its broader context. S Chen S Chaiken, Dual process theories in social psychology New York: Guildford Press, Chaiken S, Trope Y, 1999 73 96
7. The genetics of nicotine dependence. MD Li, Curr Psychiatry Rep 2006 8 158 164 10.1007/s11920-006-0016-0 16539894
8. A meta-analysis of estimated genetic and environmental effects on smoking behavior in male and female adult twins. MD Li R Cheng JZ Ma GE Swan, Addiction 2003 98 23 31 10.1046/j.1360-0443.2003.00295.x 12492752
9. Genetics and smoking behavior. RA Schnoll TA Johnson C Lerman, Curr Psychiatry Rep 2007 9 349 357 10.1007/s11920-007-0045-3 17915073
10. Genetics and smoking cessation: Improving outcome in patients at risk. C Lerman RA Schnoll MR Munaf American Journal of Preventive Medicine 2007 33 398 S405 10.1016/j.amepre.2007.09.006 18021915
11. Smoking cessation treatment: Pharmacogenetic assessment. MR Munaf C Lerman R Niaura AE Shields GE Swan, Current Opinion in Molecular Therapeutics 2005 7 202 208 15977416
12. Pharmacogenetics and nicotine addiction treatment. MR Munaf AE Shields WH Berrettini F Patterson C Lerman, Pharmacogenomics 2005 6 211 223 10.1517/14622416.6.3.211 16013953
13. Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. Y Zhang D Wang AD Johnson AC Papp W Sadee, J Biol Chem 2005 280 32618 32624 10.1074/jbc.M504942200 16046395
14. Single nucleotide polymorphism in the human mu-opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. C Bond KS LaForge M Tian D Melia S Zhang L Borg J Gong J Schluger JA Strong SM Leal JA Tischfield MJ Kreek L Yu, Proc Natl Acad Sci USA 1998 95 9608 9613 10.1073/pnas.95.16.9608 9689128
15. A single nucleotide polymorphic mutation in the human mu-opioid receptor severely impairs receptor signaling. K Befort D Filliol FM Decaillot C Gaveriaux-Ruff MR Hoehe BL Kieffer, J Biol Chem 2001 276 3130 3137 10.1074/jbc.M006352200 11067846
16. Effect of the A118G polymorphism on binding affinity, potency and agonist-mediated endocytosis, desensitization, and resensitization of the human muopioid receptor. A Beyer T Koch H Schroder S Schulz V Hollt, J Neurochem 2004 89 553 560 10.1111/j.1471-4159.2004.02340.x 15086512
17. The functional mu opioid receptor (OPRM1) Asn40Asp variant predicts short-term response to nicotine replacement therapy in a clinical trial. C Lerman EP Wileyto F Patterson M Rukstalis J Audrain-McGovern S Restine PG Shields V Kaufmann D Redden N Benowitz WH Berrettini, Pharmacogenomics Journal 2004 4 184 192 10.1038/sj.tpj.6500238 15007373
18. Association of the mu-opioid receptor gene with smoking cessation. MR Munaf KM Elliot MFG Murphy RT Walton EC Johnstone, The Pharmacogenomics Journal 2007 7 353 361 10.1038/sj.tpj.6500432 17224915
19. Self-regulation and the behavioural response to DNA risk information: A theoretical analysis and framework for future research. TM Marteau J Weinman, Social Science & Medicine 2006 62 6 1360 1368
20. Effects of etiology on perceived helpfulness of treatments for depression. MG Iselin ME Addis, Cognitive therapy and research 2003 27 205 222 10.1023/A:1023513310243 (Pubitemid 38979749)
21. Psychological impact of genetic testing for familial hypercholesterolemia within a previously aware population: A randomized controlled trial. T Marteau V Senior SE Humphries M Bobrow T Cranston MA Crook L Day M Fernandez R Horne A Iversen Z Jackson J Lynas H Middleton-Price R Savine J Sikorski M Watson J Weinman, AS Wierzbicki R Wray, American Journal of Medical Genetics 2004 128A 285 293 10.1002/ajmg.a.30102 15216550
22. Effects of attributing serious mental illnesses to genetic causes on orientations to treatment. JC Phelan LH Yang R Cruz-Rojas, Psychiatric Services 2006 57 382 387 10.1176/appi.ps.57.3.382 16524997
23. The impact of learning of a genetic predisposition to nicotine dependence: an analogue study. AJ Wright J Weinman TM Marteau, Tobacco Control 2003 12 227 230 10.1136/tc.12.2.227 12773736
24. Incorporating genetic susceptibility feedback into a smoking cessation program for African-American smokers with low income. CM McBride G Bepler IM Lipkus P Lyna G Samsa J Albright S Datta BK Rimer, Cancer Epidemiology, Biomarkers & Prevention 2002 11 521 528
25. Medication adherence in patients who have heart failure: A review of the literature. JR Wu DK Moser TA Lennie PV Burkhart, Nursing Clinics of North America 2008 43 133 153 10.1016/j.cnur.2007.10.006 18249229
26. Use of more nicotine lozenges leads to better success in quitting smoking. S Shiffman, Addiction 2007 102 809 814 10.1111/j.1360-0443.2007.01791.x 17493108
27. Effect of nicotine lozenges on affective smoking withdrawal symptoms: Secondary analysis of a randomized, double-blind, placebo-controlled clinical trial. S Shiffman, Clinical Therapeutics 2008 30 8 1461 1475 10.1016/j.clinthera.2008.07.019 18803988
28. st 2009)
29. Illness causal attributions: an exploratory study of their structure and associations with other illness cognitions and perceptions of control. S Shiloh D Rashuk-Rosenthal Y Benyamini, J Behav Med 2002 25 373 394 10.1023/A: 1015818532390 12136498
30. A simple salting out procedure for extracting DNA from human nucleated cells. SA Miller DD Dykes HF Potesky, Nucleic Acids Research 1988 6 3 1215 10.1093/nar/16.3.1215
31. Managing smoking cessation. P Aveyard R West, British Medical Journal 2007 335 7609 37 41 10.1136/bmj.39252.591806.47 17615224
32. Nicotine replacement therapy for smoking cessation. C Silagy T Lancaster L Stead D Mant G Fowler, Cochrane Database of Systematic Reviews 2004 3 D000146
33. Nicotine replacement therapy for smoking cessation (Review). LF Stead R Perera C Bullen D Mant T Lancaster, Cochrane Database of Systematic Reviews 2008 1
34. Withdrawal-oriented Therapy for Smokers. P Hajek, British Journal of Addiction 1989 84 591 598 10.1111/j.1360-0443.1989.tb03474.x 2752191
35. Learning Outcomes for Training Stop Smoking Specialists. NCSCT (NHS Centre for Smoking Cessation and Training), London: NCSCT 2010
36. The Fagerstrom Test for Nicotine Dependence: a revision of the Fagerstrom Tolerance Questionnaire. TF Heatherton LT Kozlowski RC Frecker KO Fagerstrom, British Journal of Addiction 1991 86 119 127 10.1111/j.1360-0443.1991.tb01879.x
37. Weekly versus basic smoking cessation support in primary care: a randomised controlled trial. P Aveyard K Brown C Saunders A Alexander E Johnstone MR Munaf M Murphy, Thorax 2007 62 898 903 10.1136/thx.2006.071837 17483139
38. National Institute for Health and Clinical Excellence, Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation 2002 http://www.nice.org.uk/cat.asp?c=30590 Retrieved September 08, 2008
39. Measures of abstinence in clinical trials: issues and recommendations. JR Hughes JP Keely RS Niaura DJ Ossip-Klein RL Richmond GE Swan, Nicotine &Tobacco Research 2003 5 13 25
40. Outcome criteria in smoking cessation trials: proposal for a common standard. R West P Hajek L Stead J Stapleton, Addiction 2005 100 299 303 10.1111/j.1360-0443.2004.00995.x 15733243
41. Nicodermal patch adherence and its correlates. AI Alterman P Gariti TG Cook A Cnaan, Drug & alcohol dependence 1999 53 159 165